Information Provided By:
Fly News Breaks for February 27, 2015
GILD
Feb 27, 2015 | 07:37 EDT
Deutsche Bank removed Gilead from the short-term buy list due to a 6-month automatic time removal.
News For GILD From the Last 2 Days
GILD
Apr 26, 2024 | 08:48 EDT
TD Cowen lowered the firm's price target on Gilead to $85 from $90 and keeps a Buy rating on the shares. The firm said the 5% product sales beat was led by Veklury with an assist from the liver disease franchise and HIV, while legacy HCV cell therapy and Trodelvy partially offset.
GILD
GILD
Apr 26, 2024 | 08:05 EDT
RBC Capital lowered the firm's price target on Gilead to $74 from $76 and keeps a Sector Perform rating on the shares. The company's solid quarter, helped by flagship drug Biktarvy in the face of seasonal conerns, may help convince some investors that shares have bottomed out, as its core businesses remain relatively stable and there are more catalysts in the second half of the year, the analyst tells investors in a research note. That said, growth off Gilead's high revenue base remains challenging, especially with medium-term headwinds to HIV, oncology, and CAR-T, the firm added.
GILD
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
GILD
Apr 25, 2024 | 16:03 EDT
Consensus $3.67. Sees FY24 product sales $27.1B-$27.5B.
GILD
Apr 25, 2024 | 16:02 EDT
Reports Q1 revenue $6.7B, consensus $5.92B. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024."
GILD
GILD
GILD
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.